Market Herald logo

Subscribe

Be the first with the news that moves the market

Noxopharm has released data from its first set of pre-clinical studies and has confirmed idronoxil (IDX), used in the anti-cancer drug (Veyonda), activates the immune system.

The results confirm IDX activates cells, in both the innate and adaptive immune systems, which increases natural killer and T-helper cells.

These activated cells are then able to attack and clear harmful cells from the body.

While other drugs are limited in their effectiveness, Veyonda targets a wide range of cancerous cells and CEO Greg van Wyk believes it will be beneficial in the future.

“Veyonda appears to be a truly versatile drug candidate, with these immune-oncology effects having the potential to complement its radio-enhancing and chemo-enhancing functions across a broad range of cancer types,” he said.

While the global market for immune checkpoints was US$10.5 billion in 2017, it is projected to reach US$56 billion by 2025, based on what the rate of advancement is currently like.

The discovery of Veyonda is a potential means of overcoming the restricted benefit of current anti-cancer drugs with future studies done by Noxopharm focusing on how it works.

Please find announcement attached here 

NOX by the numbers
More From The Market Herald
The Market Herald Video

" X2M Connect (ASX:X2M) completes $3.97m entitlement offer

Internet-of-Things technology company X2M Connect (ASX:X2M) has completed its $3.97 million entitlement offer.
The Market Herald Video

" Antisense Therapeutics (ASX:ANP) shares rise on long COVID-19 study

Antisense Therapeutics (ASX:ANP) announces the initial outcomes of its collaboration to study the neurological aspects of…
The Market Herald Video

" Immuron (ASX:IMC) shifts focus to therapeutic drug candidate

Immuron (ASX:IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug…
The Market Herald Video

" Bod Australia (ASX:BOD) awarded US Hemp Authority certificate for CBD extract

Bod Australia (ASX:BOD) has been awarded US Hemp Authority Certification for its exclusive CBD extract and…